98%
921
2 minutes
20
Background: Treatment planning in radiation therapy (RT) is performed on image sets acquired with commercial x-ray computed tomography (CT) scanners. Considering an increased frequency of verification scans for adaptive RT and the advent of alternatives to x-ray CTs, there is a need to review the requirements for image sets used in RT planning.
Purpose: This study aims to derive the required image quality (IQ) for the computation of the dose distribution in proton therapy (PT) regarding spatial resolution and the combination of spatial resolution and noise. The knowledge gained is used to explore the potential for dose reduction in tomography-guided PT.
Methods: Mathematical considerations indicate that the required spatial resolution for dose computation is on the scale of the set-up margins fed into the robust optimization. This hypothesis was tested by processing retrospectively 12 clinical PT cases, which reflect a variety of tumor localizations. Image sets were low-pass filtered and were made noisy in a generic manner. Dose distributions on the modified CT scans were computed with a Monte-Carlo dose engine. The similarity of these dose distributions with clinical ones was quantified with the gamma-index (1 mm/1%). The potential reduction of the x-ray exposure compared to the planning CT scan was estimated.
Results: Dose distributions within the irradiated volume were robust against low-pass filtering of the CTs with kernels up to a full-width-at-half-maximum of 4 mm, that is, the gamma pass rate (1 mm/1%) was 98%. The limit of the filter width was 6 mm for brain tumors and 8 mm for targets in the abdomen. These pass rates remained approximately unchanged if a limited amount of noise was added to the CT image sets. The estimated potential reductions of the x-ray exposure were at least a factor of 20.
Conclusions: The requirements on IQ in terms of spatial resolution in combination with noise for computing the dose in PT are clearly lower than the IQ of current clinical planning. The results apply, for example, to ultra-low dose x-ray CTs, proton CTs with coarse spatial detection, and attenuation images from the joint reconstruction of time-of-flight PET scans.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11788265 | PMC |
http://dx.doi.org/10.1002/mp.17530 | DOI Listing |
Mol Ther Methods Clin Dev
June 2025
Université Paris-Saclay, University Evry, Inserm, Genethon, Integrare Research Unit UMR_S951, 91000 Evry, France.
Pompe disease is a glycogen storage disorder caused by mutations in the acid α-glucosidase (GAA) gene, leading to reduced GAA activity and glycogen accumulation in heart and skeletal muscles. Enzyme replacement therapy with recombinant GAA, the standard of care for Pompe disease, is limited by poor skeletal muscle distribution and immune responses after repeated administrations. The expression of GAA in muscle with adeno-associated virus (AAV) vectors has shown limitations, mainly the low targeting efficiency and immune responses to the transgene.
View Article and Find Full Text PDFMol Ther Methods Clin Dev
June 2025
Shanghai Vitalgen BioPharma Co., Ltd., Shanghai 201210, China.
Bietti crystalline dystrophy (BCD) is an autosomal recessive disorder caused by loss-of-function mutations in the gene, characterized by crystal-like lipid deposits in the retina, progressive photoreceptor loss, and retinal pigment epithelium (RPE) deterioration. Currently, there are no approved treatments for BCD. VGR-R01, an investigational gene therapy, uses subretinal administration of recombinant adeno-associated virus type 8 (AAV8) vector to deliver the human CYP4V2 gene.
View Article and Find Full Text PDFComput Struct Biotechnol J
August 2025
Institut de Recherche en Cancérologie de Montpellier (IRCM), Équipe Labellisée Ligue Contre le Cancer, INSERM U1194, Université de Montpellier, Institut régional du Cancer de Montpellier (ICM), Montpellier, France.
Digital twins (DTs) are emerging tools for simulating and optimizing therapeutic protocols in personalized nuclear medicine. In this paper, we present a modular pipeline for constructing patient-specific DTs aimed at assessing and improving dosimetry protocols in PRRT such as therapy. The pipeline integrates three components: (i) an anatomical DT, generated by registering patient CT scans with an anthropomorphic model; (ii) a functional DT, based on a physiologically-based pharmacokinetic (PBPK) model created in SimBiology; and (iii) a virtual clinical trial module using GATE to simulate particle transport, image simulation, and absorbed dose distribution.
View Article and Find Full Text PDFIndian J Nucl Med
August 2025
Department of Physics, Shi.C., Islamic Azad University, Shiraz, Iran.
Background: Another approach to improve the dose conformity is to use charged particles like protons instead of the conventional X- and γ-rays. Protons exhibit a specific depth-dose distribution which allows to achieve a more targeted dose deposition and a significant sparing of healthy tissue behind the tumor. In particular, proton therapy has, therefore, become a routinely prescribed treatment for tumors located close to sensitive structures.
View Article and Find Full Text PDFCureus
August 2025
Division of Radiation Oncology and Developmental Radiotherapeutics, BC Cancer - Vancouver, Vancouver, CAN.
Introduction In select tumor sites, symptom palliation and local control can be improved through delivering higher biological equivalent doses (BED) of radiotherapy. However, not all patients are suitable candidates for stereotactic body radiation therapy (SBRT). The 30 Grays in five fractions (30/5) regimen is a conformal, hypofractionated regimen that offers a higher BED compared to conventional palliative radiotherapy.
View Article and Find Full Text PDF